BCR-ABL
8 drugsBCR-ABL1 Fusion Gene (Philadelphia Chromosome)
Predictive biomarker for patient selection in 8 indications
Understanding BCR-ABL
What it means: BCR-ABL results from a translocation creating the Philadelphia chromosome. The fusion protein has constitutive tyrosine kinase activity.
Why it matters: Tyrosine kinase inhibitors (imatinib, dasatinib, nilotinib, ponatinib) revolutionized CML treatment, achieving long-term remissions.
Testing: Tested via cytogenetics, FISH, or RT-PCR. Quantitative PCR monitors treatment response (molecular response levels).
8
Approved Drugs
8
Indications
7
Companies
Search BCR-ABL Clinical Trials
Search recruiting trials on ClinicalTrials.gov